| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 02/05/2009 | US20090035217 Truncated Fragments of Alpha-Synuclein in Lewy Body Disease |
| 02/05/2009 | US20090035216 Method for determining in vivo biopharmaceutical concentration or bioavailability |
| 02/05/2009 | US20090035215 Radiofluorination |
| 02/05/2009 | DE102007034956A1 Verfahren zum Detektieren einer neuropathologisch veränderten Gehirnregion A method for detecting a neuro-pathologic brain region |
| 02/05/2009 | CA2694102A1 Optical imaging agents |
| 02/04/2009 | EP2020443A2 Glycine-N-methyltransferase (GNMT) knockout mouse model and use thereof |
| 02/04/2009 | EP2020244A1 Magnetic resonance contrast medium using polyethylene glycol and magnetic resonance image pick-up method |
| 02/04/2009 | EP2019667A2 Detection and imaging of target tissue |
| 02/04/2009 | EP1494584A4 Endohedral metallofullerene contrast agents |
| 02/04/2009 | CN101360515A Fluorescent nanoparticles |
| 02/04/2009 | CN101357232A Thermally crosslinked contrast agents |
| 02/04/2009 | CN100457189C Fusions of cytokines and tumor targeting proteins |
| 02/04/2009 | CN100457188C Implantable particles for tissue bulking and the treatment of gastroesophageal reflux diosease |
| 02/03/2009 | US7485753 Cyclopropane scaffolding moiety having three iodinated phenyl groups bound thereto; less renal toxicity, improved viscosity, iodine concentration and solubility |
| 02/03/2009 | US7485284 In a population of subjects with the defect, measuring a change in the presence of lung infection in subjects who have been administered the agent in comparison those who have not; the agents tested lack intrinsic antibiotic activity |
| 02/03/2009 | US7485283 imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging. |
| 01/29/2009 | WO2009014605A2 Methods and systems relating to mitochondrial dna phenotypes |
| 01/29/2009 | WO2009014201A1 Process for production of surface-coated inorganic particles |
| 01/29/2009 | WO2009013692A2 Multimodality matching medium for diffuse optical tomography and ultrasound measurements |
| 01/29/2009 | WO2009013350A2 Imaging medium comprising hyperpolarised 13 c-lactate and use thereof |
| 01/29/2009 | WO2008136773A8 Functionalization of nanoparticles by glucosamine derivatives |
| 01/29/2009 | US20090030308 Systems, compositions, and methods for local imaging and treatment of pain |
| 01/29/2009 | US20090030117 comprises alginates; anticancer agents; therapeutic vascular occlusions (embolizations) |
| 01/29/2009 | US20090030065 Use of Pde1c and Inhibitors Thereof |
| 01/29/2009 | US20090029361 Growth differentiation factor-7 |
| 01/29/2009 | US20090028867 Antagonists Specific For Denatured Collagen And Methods Of Using Same |
| 01/29/2009 | US20090028799 Contrast agents |
| 01/29/2009 | US20090028798 Method for determining redox status of a tissue |
| 01/29/2009 | US20090028797 Novel polymeric ultrasound contrast agent and methods of making thereof |
| 01/29/2009 | US20090028796 Pesticidal composition comprising indole derivates |
| 01/29/2009 | US20090028795 NOD1 as an Anti-Tumor Agent |
| 01/29/2009 | US20090028794 Uses and compositions for treatment of psoriatic arthritis |
| 01/29/2009 | US20090028793 Vascular Tumor Markers |
| 01/29/2009 | US20090028792 Nano-particle surface modification |
| 01/29/2009 | US20090028790 Labelled adrenomedullin derivatives and their use for imaging and therapy |
| 01/29/2009 | US20090028789 Methods for detecting parenchymal plaques in vivo |
| 01/29/2009 | US20090028788 Compounds having rd targeting motifs |
| 01/29/2009 | US20090028787 Novel Heteroaryl Substituted Benzothiazoles |
| 01/29/2009 | US20090028786 Methods and apparatus for imaging agents for disease detection |
| 01/29/2009 | US20090028784 Antibodies to IL-6 and use thereof |
| 01/29/2009 | CA2694536A1 Process for production of surface-coated inorganic particles |
| 01/28/2009 | EP2018163A2 Imaging agents and methods |
| 01/28/2009 | EP1699493B1 Polymeric marker with high radiopacity for use in medical devices |
| 01/28/2009 | EP1624902B1 Methods of producing carbon-13 labeled biomass |
| 01/28/2009 | EP1470129B1 Radiolabeled neuropeptide y y5 receptor antagonists |
| 01/28/2009 | EP1420689A4 Systems and methods for targeted magnetic resonance imaging of the vascular system |
| 01/28/2009 | CN101355940A In vivo or in vitro method for detecting amyloid deposits having at least one amyloidogenic protein |
| 01/28/2009 | CN101352351A Method for detecting a brain region with neurodegenerative change |
| 01/28/2009 | CN100455574C Thiazoline acid derivatives |
| 01/27/2009 | US7482507 Methods of screening agents for activity using teleosts |
| 01/27/2009 | US7482114 In vivo assay and molecular markers for testing the phenotypic stability of cell populations, and selected cell populations for autologous transplantation |
| 01/27/2009 | CA2466808C Formulations for use in medical or diagnostic procedures |
| 01/27/2009 | CA2221513C Fluorochemical liquid augmented cryosurgery |
| 01/22/2009 | WO2009012288A2 Trifunctional imaging agent for monoclonal antibody tumor-targeted imaging |
| 01/22/2009 | WO2009011589A1 A microsphere comprising an organic lanthanide metal complex |
| 01/22/2009 | WO2008125422A3 Use of metal nanoparticles for diagnosing alzheimer disease |
| 01/22/2009 | WO2008087017A3 Novel cascade polymer complexes, method for their production and pharmaceutical agents containing the same |
| 01/22/2009 | WO2008079834A3 Preparation of paramagnetic nanoparticles conjugated to leukotriene b4 (ltb4) receptor antagonists, and their use as mri contrast agents for the detection of infection and inflammation |
| 01/22/2009 | WO2001092300A9 Chimeric gfp-aequorin as bioluminescent ca++ reporters at the single cell level |
| 01/22/2009 | US20090024108 Methods and Devices for Delivery of Compositions to Conduits |
| 01/22/2009 | US20090023928 Phthalamide-lanthanide complexes for use as luminescent markers |
| 01/22/2009 | US20090023632 Hemoglobin-haptoglobin complexes |
| 01/22/2009 | US20090022668 Mri contrast agents endowed with concentration independent responsiveness |
| 01/22/2009 | US20090022667 METHODS OF TREATING COGNITIVE DISORDERS BY INHIBITION OF Gpr12 |
| 01/22/2009 | US20090022666 Methods and systems relating to mitochondrial DNA information |
| 01/22/2009 | US20090022665 Evaluation Of Immediate-Effect Skin Molding Agents Using DISC |
| 01/22/2009 | US20090022659 Antibodies to TNF alpha and use thereof |
| 01/22/2009 | US20090022656 Lipidated glycoprotein particles and methods of use |
| 01/22/2009 | DE102007032799A1 New sugar-containing polypyridine metal complexes e.g. useful as fluorescence markers in biological systems or for treating abnormal cells |
| 01/22/2009 | CA2694003A1 A microsphere comprising an organic lanthanide metal complex |
| 01/21/2009 | EP2017253A1 A particle comprising an organic lanthanide metal complex |
| 01/21/2009 | EP2016090A2 Genetic adjuvants for viral vaccines |
| 01/21/2009 | EP2016046A1 Contrast agents |
| 01/21/2009 | EP2015784A2 Magnetic resonance imaging contrast agents synthesized using ring-opening metathesis polymerization |
| 01/21/2009 | EP2015783A2 Method for testing drug sensitivity in solid tumors by quantifying mrna expression in thinly-sliced tumor tissue |
| 01/21/2009 | EP1590004B1 Process for the production of improved thickened beverages for dysphagia |
| 01/21/2009 | EP1294906B1 Whole-body optical imaging of gene expression and uses thereof |
| 01/21/2009 | EP0711127B2 Methods of preparing gas-filled liposomes |
| 01/21/2009 | CN101351454A Pyrazine derivatives and uses thereof in renal monitoring |
| 01/21/2009 | CN101351202A Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms |
| 01/21/2009 | CN101347625A Thrombus target contrast agent of magnetic nuclear resonance and preparation method thereof |
| 01/21/2009 | CN101347624A Construction method of animal model with diabetes skin ulcer |
| 01/21/2009 | CN101347623A Multifunctional nanodevice platform |
| 01/20/2009 | US7479546 Pro104 antibody compositions and methods of use |
| 01/20/2009 | US7479367 In vivo assay and molecular markers for testing the phenotypic stability of cell populations and selected cell populations for autologous transplantation |
| 01/20/2009 | US7479288 Nanoparticulate preparation |
| 01/20/2009 | US7479278 Troponin I polypeptide fragments and uses thereof |
| 01/20/2009 | CA2423252C Photosensitisers |
| 01/20/2009 | CA2306795C Acetic acid as contrast agent in fluorescence spectroscopy |
| 01/20/2009 | CA2294199C Method for enhancing the echogenicity and decreasing the attenuation of microencapsulated gases |
| 01/20/2009 | CA2137822C Method for detecting pre-cancerous or cancerous cells using p90 antibodies or probes |
| 01/15/2009 | WO2009009776A2 Patient selection and therapeutic methods using markers of prostaglandin metabolism |
| 01/15/2009 | WO2009009179A2 Non-invasive molecular imaging of cellular histone deacetylase substrate using magnetic resonance spectroscopy (mrs) or positron emission tomography (pet) |
| 01/15/2009 | WO2009008734A2 Contrast agents |
| 01/15/2009 | WO2009008489A1 Antibody liposome |
| 01/15/2009 | WO2008140779A3 Methods for diagnosing diseases and evaluating treatments therefor using pet |
| 01/15/2009 | WO2008071679A9 Fibrin binding peptide conjugates for diagnostic and therapeutic applications. |
| 01/15/2009 | WO2005096919A3 Methods of measuring ejaculatory latency times |
| 01/15/2009 | US20090019554 Targeted cell death |
| 01/15/2009 | US20090016965 Internal image antibodies for optical imaging and therapy |